ESPONDILODISCITE PIOGÊNICA: FATORES DE RISCO PARA FALHA TERAPÊUTICA E RECORRÊNCIA

Danda, Guilherme José da Nóbrega; Castro, Cleudson Nery de

Brasil

Español English

Original article, Tumor/Infection • Coluna/Columna. 22 (2) • 2023 • https://doi.org/10.1590/S1808-185120232202268880 copiar

ESPONDILODISCITE PIOGÊNICA: FATORES DE RISCO PARA FALHA TERAPÊUTICA E RECORRÊNCIA

Autoria SCIMAGO INSTITUTIONS RANKINGS

RESUMO:

Objetivo:

Avaliar os fatores prognósticos associados à falha terapêutica e à recorrência na espondilodiscite piogênica (EP).

Métodos:

Um estudo de coorte histórica foi conduzido em um hospital brasileiro de referência nas doenças do sistema locomotor e do neurodesenvolvimento. Todos os pacientes com EP tratados entre janeiro de 1999 e dezembro de 2018 e acompanhados por pelo menos um ano foram incluídos. A EP foi definida com base em critérios clínicos, laboratoriais e radiológicos. Dados microbiológicos e desfechos clínicos ao final do tempo de seguimento também foram coletados e analisados.

Resultados:

Cinquenta pacientes (idade média 50,94 ± 15,84 anos, homem 76,00%) foram incluídos. Depois de doze meses de seguimento, a falha terapêutica foi observada em 24,00% (n = 12) e a recorrência em 18,00% (n = 09) dos pacientes. Entre os que curaram, sintomas residuais foram constatados em 50,00% (19/38). Nenhuma morte foi observada. Após análise multivariada, a falha terapêutica foi associada à prescrição de antibioticoterapia antes dos resultados de cultura (p = 0,0153), compressão medular (p = 0,0053) e déficits sensoriais (p = 0,0341). Além disso, a recorrência esteve associada a cirurgias não espinhais prévias (p = 0,0350) e à compressão medular (p = 0,0447).

Conclusão:

A EP causa morbidade significativa. O prognóstico depende principalmente da apresentação clínica na admissão, especialmente da existência de compressão medular, o que reforça a importância do diagnóstico precoce. Nível de Evidência II; Estudos de Prognóstico.

Descritores:
Discite; Prognóstico; Resultado do Tratamento

Characteristics	Values ^* * Values expressed as mean ± standard deviation or frequency (%). 1. Only two patients were under 18. 2. Malignancy, intravenous drug abuse, end-stage renal disease, congestive heart failure, hepatitis C virus, and previous tuberculosis were reported only once each. 3. There was no record of spondylodiscitis by a contiguous focus of infection.
Age (years)¹1 Akiyama T, Chikuda H, Yasunaga H, Horiguchi H, Fushimi K, Saita K. Incidence and risk factors for mortality of vertebral osteomyelitis: a retrospective analysis using the Japanese diagnosis procedure combination database. BMJ Open. 2013;3(3):e002412.	50.94 ± 15.84
Sex
Male	38 (76.00)
Female	12 (24.00)
Diagnostic delay (months)	6.32 ± 5.27
Clinical manifestations
Back pain	48 (96.00)
Fever	16 (32.00)
Weight loss	20 (40.00)
Radicular pain	18 (36.00)
Neurological deficit (motor or sensory)	11 (22.00)
Spinal deformities	7 (14.00)
Risk factors ²2 Issa K, Diebo BG, Faloon M, Naziri Q, Pourtaheri S, Paulino CB, et al. The Epidemiology of vertebral osteomyelitis in the United States from 1998 to 2013. Clin Spine Surg. 2018;31(2):E102-8.
Diabetes mellitus	6 (12.00)
Hypertension	21 (42.00)
Smoking	7 (14.00)
Alcoholism	8 (16.00)
Disc herniation	13 (26.00)
Spinal osteoarthritis	21 (42.00)
Rheumatological disease	2 (4.00)
Use of immunosuppressive agents	6 (12.00)
Distant bacterial infections (last year)	24 (48.00)
Hospitalization in the last three years	34 (68.00)
Invasive spinal procedures (last three years)	24 (48.00)
Surgery in the last three years (nonspinal)	8 (16.00)
Pathophysiological classification ³3 Lora-Tamayo J, Euba G, Narváez JA, Murillo O, Verdaguer R, Sobrino B, et al. Changing trends in the epidemiology of pyogenic vertebral osteomyelitis : the impact of cases with no microbiologic diagnosis. Semin Arthritis Rheum. 2011;41(2):247-55.
Hematogenous spondylodiscitis	29 (58.00)
Spondylodiscitis by direct inoculation	21 (42.00)

Characteristics	Values ^* * Values expressed as frequency (%).
Affected level
Cervical	2 (4.00)
Thoracic	9 (18.00)
Thoracolumbar	4 (8.00)
Lumbar	21 (42.00)
Lumbosacral	14 (28.00)
Number of vertebrae affected
Two vertebrae	40 (80.00)
More than two vertebrae	10 (20.00)
Complications
Psoas abscess	1 (2.00)
Paravertebral abscess	8 (16.00)
Epidural abscess	5 (10.00)
Paravertebral phlegmon	9 (18.00)
Epidural phlegmon	4 (8.00)
Spinal cord compression	8 (16.00)
Cauda equina compression	2 (4.00)

Characteristics	Values *
Treatment modalities
Nonsurgical	33 (66.00)
Surgical	17 (34.00)
Use of orthoses	38 (76.00)
Type of antibiotic therapy
Exclusively empiric therapy	11 (22.00)
Exclusively definitive therapy based on microbiology results	28 (56.00)
Empiric followed by definitive therapy based on microbiology results	11 (22.00)
Antimicrobial treatment time (weeks)
Intravenous	5.07 ± 2.49
Oral	4.44 ± 2.89
Total	9.33 ± 3.08
Hospital length of stay (days)	55.88 ± 31.22
Outcomes - during one-year follow-up
Deaths	0 (0.00)
Recurrence	9 (18.00)
Outcomes – in the first medical evaluation after a one-year follow-up
Cured without sequelae	19 (38.00)
Cured with sequelae (neurological impairment or chronic pain)	19 (38.00)
Therapeutic failure	12 (24.00)

	Risk Relative (RR)		RR Adjusted
Variables	RR (95 % CI)	p-value	RR (95% IC)	p-value
Diagnostic delay > 6 months	1.93 (0.71 – 5.26)	0.1967	2.23 (0.50 – 9.89)	0.2923
Alcoholism	2.62 (1.03 – 6.67)	0.0424	1.99 (0.54 – 7.34)	0.3037
Surgery in the last three years (nonspinal)	2.62 (1.03 – 6.67)	0.0424	1.30 (0.22 – 7.73)	0.7755
Spondylodiscitis (pathophysiological classification)		0.0605		0.2328
Direct inoculation	2.76 (0.96 – 7.98)	0.0605	2.29 (0.59 – 8.91)	0.2328
Hematogenous	1	-	1	-
Spinal cord compression (imaging evaluation)	3.75 (1.58 – 8.89)	0.0027	5.27 (1.64 – 16.95)	0.0053
More than two vertebrae affected	2.86 (1.14 – 7.13)	0.0245	2.14 (0.46 – 9.98)	0.3303
Type of antibiotic therapy		0.1343		0.0260
Exclusively empiric therapy	0.42 (0.06 – 3.13)	0.4005	1.05 (0.11 – 9.80)	0.9688
Exclusively definitive therapy based on microbiology results	1	-	1	-
Empiric followed by definitive therapy based on microbiology results	2.12 (0.81 – 5.54)	0.1248	3.82 (1.29 – 11.27)	0.0153
Sensory deficit at admission	2.27 (0.86 – 5.88)	0.0925	4.76 (1.12 – 20.17)	0.0341
Total antimicrobial treatment time > eight weeks	2.35 (0.81 – 6.80)	0.1158	1.90 (0.43 – 8.37)	0.3963
Pyogenic spondylodiscitis caused by multidrug-resistant bacteria¹ 1 Methicillin-resistant Staphylococcus aureus (n= 06), multidrug-resistant Pseudomonas aeruginosa (n= 02), and extended-spectrum β-lactamase producing Gram-negative bacteria (n= 02).	4.00 (1.63 – 9.78)	0.0024	0.97 (0.23 – 4.04)	0.9666

	Hazard Ratio (HR)		HR Adjusted
Variables	HR (95 % IC)	p-value	HR (95 % IC)	p-value
Age ≥ 60 years old	5.44 (0.67 – 43.86)	0.1119	3.55 (0.27 – 46.62)	0.3347
Hypertension	3.40 (0.75 – 15.38)	0.1120	2.28 (0.39 – 13.44)	0.3607
Nonspinal surgeries in the last three years	9.35 (1.71 – 51.11)	0.0099	5.74 (1.00 – 34.37)	0.0350
Erythrocyte sedimentation rate > 15 mm in the first hour at admission	4.45 (0.47 – 42.28)	0.1934	3.93 (0.21 – 72.27)	0.3573
Spinal cord compression (imaging evaluation)	5.94 (1.56 – 22.57)	0.0089	3.83 (1.00 – 15.97)	0.0447
Pyogenic spondylodiscitis caused by multidrug-resistant bacteria¹ 1 Methicillin-resistant Staphylococcus aureus (n= 06), multidrug-resistant Pseudomonas aeruginosa (n= 02), and extended-spectrum β-lactamase-producing Gram-negative bacteria (n= 02).	2.67 (0.66 – 10.82)	0.1693	0.38 (0.03 – 4.32)	0.4346

	Therapeutic failure			Recurrence
Variables*	Yes	No	p-value **	Yes	No	p-value**
Etiological Agent			0.2088			0.2141
Staphylococcus aureus	5 (26.32)	14 (73.68)		6 (31.58)	13 (68.42)
Other Gram-positive	2 (20.00)	8 (80.00)		1 (10.00)	9 (90.00)
Gram-negative	4 (40.00)	6 (60.00)		2 (20.00)	8 (80.00)
Negative culture	0 (0.00)	9 (100.00)		0 (0.00)	9 (100.00)
No culture collected	1 (50.00)	1 (50.00)		0 (0.00)	2 (100.00)
Spine segments			0.305			0.406
Cervical	1 (50.00)	1 (50.00)		1 (50.00)	1 (50.00)
Thoracic	3 (33.33)	6 (66.67)		2 (22.22)	7 (77.78)
Thoracolumbar	2 (50.00)	2 (50.00)		1(25.00)	3 (75.00)
Lumbar	5 (23.81)	16 (76.19)		5 (23.81)	16 (76.19)
Lumbosacral	1 (7.14)	13 (92.86)		0 (0.00)	14 (100.00)
Treatment modalities			0.294			0.465
Nonsurgical	6 (18.18)	27 (81.82)		5 (15.15)	28 (84.85)
Surgical	6 (35.30)	11 (64.70)		4 (23.53)	13 (76.47)

Sociedade Brasileira de Coluna Al. Lorena, 1304 cj. 1406/1407, 01424-001 São Paulo, SP, Brasil, Tel.: (55 11) 3088-6616 - São Paulo - SP - Brazil
E-mail: coluna.columna@uol.com.br

Acompanhe os números deste periódico no seu leitor de RSS

[1] Correspondence: Guilherme José da Nóbrega Danda. Hospital Sarah Brasília, SMHS 501 Bloco A, Brasília, DF, Brazil. 70335901. guilhermedanda@yahoo.com.br